VK2735 Complete Guide: Viking’s Dual Agonist Contender

Introduction

VK2735 is Viking Therapeutics’ bet that it can challenge tirzepatide with the same GLP-1 plus GIP mechanism, delivered in both injectable and oral forms. Early phase 2 data look strong, especially the speed of weight loss in the injectable trial, which is why the drug gets so much attention from investors and patients alike. But it is still investigational. You cannot get it yet.

This complete guide covers what VK2735 is, how it works, what the trial numbers show, where the oral version fits, and how to think about a pipeline drug when you are making real decisions today.

At TrimRx, we think understanding the pipeline helps you separate genuine progress from hype. If you want to explore what is actually available right now, the free assessment quiz is a simple place to begin.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is VK2735?

VK2735 is an investigational dual agonist developed by Viking Therapeutics, a US biotech. It activates two receptors: GLP-1 and GIP, the same combination used by tirzepatide.

Quick Answer: VK2735 is a GLP-1 and GIP dual agonist from Viking Therapeutics, the same receptor pair as tirzepatide.

The drug is unusual because Viking is developing it in two formats at once. There is a weekly subcutaneous injectable, the more advanced program, and a daily oral tablet that uses the same molecule. Most companies pick one route. Viking is pursuing both, which gives VK2735 flexibility if it reaches the market.

It is a real, clinical-stage candidate with published phase 2 data, not an early lab concept. But it is not approved, and as of 2026 you cannot get a prescription for it.

How Does VK2735 Work?

VK2735 activates the GLP-1 receptor and the GIP receptor together. The GLP-1 arm suppresses appetite, slows gastric emptying, and improves blood sugar control. The GIP arm complements it, appearing to improve fat handling and possibly tolerability.

This is the same mechanistic logic behind tirzepatide. Two complementary incretin pathways tend to produce larger weight loss than a single GLP-1 drug, a pattern that has held across the dual-agonist class.

Because it shares tirzepatide’s targets rather than adding glucagon like survodutide or mazdutide, VK2735 is best understood as a direct competitor to tirzepatide rather than a different category of drug.

What Does the Injectable Phase 2 Data Show?

The injectable program is VK2735’s headline. Its phase 2 obesity trial reported strong weight loss, with mean reductions reaching the mid-teens percentage range at higher doses over a relatively short period of roughly 13 weeks.

That speed is what caught attention. Many obesity trials run 68 to 72 weeks. Seeing double-digit weight loss in about three months suggests a steep early response curve, though short trials cannot tell you where weight loss plateaus over a full year.

The data are genuinely promising. But phase 2 is not phase 3, and short trials do not establish durability, long-term safety, or how the drug performs across a broad population.

What About the Oral Version?

VK2735 also has an oral formulation in development, which is a big deal because most potent GLP-1 dual agonists are injectables. An effective oral pill would lower the barrier for people who dislike needles.

Oral peptide delivery is hard. The molecule has to survive the digestive tract and absorb well enough to work. Viking has reported early oral data and is advancing the program, but the oral format is earlier in development than the injectable.

If both formats succeed, VK2735 could offer a choice between a weekly shot and a daily pill using the same molecule. That flexibility would be a real differentiator. For now, it is a promise, not a product.

How Does VK2735 Compare to Tirzepatide?

Since they share the GLP-1/GIP mechanism, VK2735 is best seen as a tirzepatide challenger. Tirzepatide is approved, has SURMOUNT-1 data showing about 20.9% weight loss at 72 weeks (Jastreboff 2022, NEJM), and years of safety follow-up.

VK2735’s phase 2 numbers are competitive on a short timeline, but it has no phase 3 weight loss figure, no long-term safety record, and no approval. Comparing a 13-week phase 2 result to a 72-week phase 3 result is not apples to apples.

The honest position: VK2735 looks like a credible competitor with real potential, but tirzepatide is the proven, available standard it would have to beat.

What Are the Likely Side Effects?

VK2735 shares the GLP-1 side effect family seen across the class: nausea, vomiting, diarrhea, constipation, and reduced appetite, usually worst during dose escalation and easing with time.

In phase 2, the drug was generally tolerated, with gastrointestinal effects as the main issue, consistent with other incretin drugs. Because it uses GLP-1/GIP rather than adding glucagon, it does not carry the heart-rate and blood-sugar considerations that glucagon agonists like survodutide require.

Long-term safety is unknown. Short phase 2 trials cannot reveal rare or delayed effects, which is one reason approval requires larger, longer studies.

When Will VK2735 Be Available?

VK2735 is not approved as of 2026 and would need to complete phase 3 trials before any FDA review. That process, plus regulatory evaluation, typically takes years.

The injectable is the more advanced program and would likely reach the market first if trials succeed. The oral version is earlier and would follow later, if at all.

For planning purposes, treat VK2735 as a drug to watch, not one to wait for. Pipeline timelines slip, and trials can fail.

Should You Wait for VK2735?

No. Waiting for an investigational drug means delaying treatment that works now. Obesity is a chronic condition, and the cost of waiting years for a pipeline candidate rarely pays off.

If VK2735 excites you, follow Viking’s trial readouts. But base your current decisions on approved, available medication with real evidence behind it.

The smartest approach is usually to start with a proven option and reassess as the field evolves.

Key Takeaway: Phase 2 injectable data showed strong weight loss, with reported reductions in the mid-teens percentage range at higher doses over roughly 13 weeks.

How VK2735 Fits the Bigger Pipeline Picture

VK2735 is one of several next-generation candidates, alongside survodutide, mazdutide, ecnoglutide, and oral options like orforglipron. The field is crowded, which is good for patients because competition tends to improve options and pricing over time.

What sets VK2735 apart is the dual-format approach and its strong, fast phase 2 injectable data. Whether that translates into a market-beating product depends on phase 3 results and the oral program’s success.

For now, it is a promising name in a deep pipeline, not a treatment you can use.

Why the Dual-format Strategy Matters

Most weight loss drugs commit to one delivery route. Viking’s decision to develop VK2735 as both an injectable and an oral pill is a strategic bet that the market wants choice. If both formats work, a patient could pick a weekly shot or a daily tablet based on lifestyle and preference.

The injectable tends to deliver more drug more reliably, which is why it usually shows the strongest weight loss numbers in this class. The oral version trades some of that potency for convenience, since oral peptide absorption is limited. That tradeoff is the central tension of every oral GLP-1 program.

For VK2735 specifically, the injectable carrying the strong phase 2 data while the oral catches up is the expected pattern. If the oral version proves it can deliver meaningful weight loss without injections, it would be a genuine differentiator in a market where most potent options require a needle.

What Investors Watch Versus What Patients Should Watch

VK2735 generates a lot of market noise because Viking is a smaller company whose value hinges heavily on this program. Stock moves on every trial readout, which can make the drug sound more imminent than it is.

Patients should filter that noise. What matters for treatment is phase 3 efficacy, long-term safety, and approval, none of which VK2735 has yet. A strong phase 2 result and a rising stock price do not put a drug in your medicine cabinet.

The disciplined approach is to track the actual clinical milestones, phase 3 enrollment, readouts, and any FDA filing, rather than headlines about market reactions. Until those milestones land, VK2735 stays a pipeline name.

How to Think About VK2735 Versus Available Drugs

The core question is simple. Do you want to wait years for a drug that might be modestly better, or start now with a proven option? For nearly everyone managing a chronic condition, starting now wins.

VK2735’s phase 2 data are encouraging, but “encouraging phase 2 data” describes many drugs that never reach the market or arrive years late. Tirzepatide and semaglutide are here, studied, and accessible, including in compounded forms through telehealth.

If VK2735 eventually launches and proves superior, switching is always an option. Starting treatment today does not lock you out of future advances.

What Muscle Preservation Looks Like on Any Dual Agonist

If VK2735 reaches the market, the muscle question will follow it just like it follows tirzepatide and semaglutide. Fast weight loss tends to take some lean mass along with fat unless you actively defend muscle.

The defense is the same regardless of drug. Eat enough protein, often cited around 1.6 grams per kilogram of body weight or higher for people in a deficit. Train against resistance two to three times a week. Avoid extreme calorie cuts that accelerate lean loss. Get enough sleep, since recovery is where muscle is preserved.

VK2735’s short, steep phase 2 weight loss curve actually raises the muscle question more, not less. Rapid loss in a 13-week window leaves little time for the body to adapt, which makes deliberate protein and training habits even more important. Any potent appetite-suppressing drug needs a muscle plan attached to it.

This is the part people skip, and it is the part that separates a good body composition outcome from a disappointing one. The drug handles appetite. You handle the muscle.

Your Path Forward with TrimRx

VK2735 may be years away, but effective treatment is available today. TrimRX offers compounded semaglutide and tirzepatide through a personalized telehealth program, with provider oversight and a focus on a complete plan including muscle protection and nutrition.

If you have been holding out for the next drug, the better move is usually to start with a proven option now. TrimRX’s free assessment quiz can show you whether a structured program fits your goals.

Bottom line: For patients who want treatment now, approved options like tirzepatide and semaglutide, including compounded versions through TrimRX, are the realistic choices.

FAQ

What Is VK2735?

VK2735 is an investigational GLP-1 and GIP dual agonist from Viking Therapeutics, developed in both injectable and oral formats. It uses the same receptor pair as tirzepatide.

Is VK2735 Available Now?

No. As of 2026 VK2735 is investigational, not approved, and not available through any pharmacy or telehealth program.

How Much Weight Does VK2735 Cause People to Lose?

Its phase 2 injectable trial reported weight loss in the mid-teens percentage range at higher doses over roughly 13 weeks. There is no phase 3 long-term figure yet.

Is VK2735 Better Than Tirzepatide?

Unknown. VK2735’s short-term phase 2 data look competitive, but tirzepatide is approved with proven 72-week results and years of safety data. No head-to-head trial exists.

Does VK2735 Come as a Pill?

Viking is developing an oral version alongside the injectable. The oral program is earlier in development, and the injectable is more advanced.

What Should I Take While VK2735 Is in Trials?

Approved options like tirzepatide and semaglutide are available now, including compounded versions through telehealth programs such as TrimRX, and carry strong trial evidence.

Who Makes VK2735?

VK2735 is developed by Viking Therapeutics, a US biotechnology company. The program is central to the company’s pipeline and gets heavy investor attention.

Does VK2735 Use the Same Mechanism as Tirzepatide?

Yes. Both activate the GLP-1 and GIP receptors. That makes VK2735 a direct mechanistic competitor to tirzepatide rather than a different class of drug like the GLP-1/glucagon agonists.

Will the Oral Version Be as Effective as the Injection?

Unknown. Oral peptide absorption is limited, so oral formats usually deliver somewhat less drug than injectables. The oral VK2735 program is earlier in development than the injectable, so its real-world efficacy is not yet established.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.